1-20 of 100
Paul M. Barr
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ready, AIM, stop: ibrutinib plus venetoclax in MCL

Clinical Trials & Observations
Danielle S. Wallace, Paul M. Barr
Journal: Blood
Blood (2024) 144 (8): 800–802.
https://doi.org/10.1182/blood.2024025021
Published: 2024
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Paolo Ghia, William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan, Zoë Hunter, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam
Journal: Blood
Blood (2023) 142 (Supplement 1): 633.
https://doi.org/10.1182/blood-2023-187128
Published: 2023
Journal Articles

Low Dose Rituximab Efficiently Clears Circulating CLL Cells and Maintains Sensitivity to Antibody Dependent Cellular Phagocytosis (ADCP)

Clare B Heffernan, Charles C Chu, Jennifer E Bruno, Christine A Herne, Andrea M Baran, Ronald P Taylor, Paul M. Barr, Michael R. Elliott, Clive S Zent
Journal: Blood
Blood (2023) 142 (Supplement 1): 6548.
https://doi.org/10.1182/blood-2023-175019
Published: 2023
Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh, Nicole Lamanna, Toby A. Eyre, Catherine C Coombs, Beenish S Manzoor, Jennifer R. Brown, Hande H. Tuncer, Chaitra S Ujjani, Lori A Leslie, Lindsey E. Roeker, Matthew S Davids, Joanna M. Rhodes, Alan Skarbnik, Nnadozie Emechebe, Isabelle Fleury, Brian T. Hill, Christopher P. Fox, Paul M. Barr, Dureshahwar Jawaid, Wendy J Sinai, Laurie K Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Stephen J. Schuster, Kaitlin Kennard, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1908.
https://doi.org/10.1182/blood-2023-179198
Published: 2023
Journal Articles

Ilyad: A Phase III Double Blind, Randomized Trial Evaluating Vitamin D (Cholecalciferol) in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

Jonathan W. Friedberg, Michael T. Brady, Strawderman Myla, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, Barbara L. Averill, Brian K. Link, Paul M. Barr, John P. Leonard, John M. Ashton, Derick R Peterson, Loretta J. Nastoupil
Journal: Blood
Blood (2023) 142 (Supplement 1): 606.
https://doi.org/10.1182/blood-2023-178088
Published: 2023
Journal Articles

Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Clive S. Zent, Jeremiah E. Moore, Paige C. Bloom, Charles C. Chu, Jennifer E. Bruno, Christine A. Herne, Andrea M Baran, Sally A. Quataert, Tim R. Mosmann, Ronald P. Taylor, Danielle S. Wallace, Michael R. Elliott, Paul M. Barr
Journal: Blood
Blood (2022) 140 (Supplement 1): 4171–4172.
https://doi.org/10.1182/blood-2022-162858
Published: 2022
Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Robert Stuver, Laure Michaud, Carla Casulo, Ranjana H. Advani, Elizabeth L. Budde, Paul M. Barr, Connie Lee Batlevi, Philip C Caron, Louis S. Constine, Savita Dandapani, Pamela Drullinsky, Jonathan W. Friedberg, Clare Grieve, Audrey Hamilton, Paul A. Hamlin, Richard Hoppe, Steven M. Horwitz, Niloufer Khan, Matthew J. Matasar, Ariela Noy, M.Lia Palomba, Heiko Schoder, David J. Straus, Shreya Vemuri, Joachim Yahalom, Joanna C. Yang, Anas Younes, Andrew D. Zelenetz, Craig H. Moskowitz, Anita Kumar, Alison J. Moskowitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 1756–1758.
https://doi.org/10.1182/blood-2022-156382
Published: 2022
Journal Articles

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

Paolo Ghia, Carolyn Owen, Jacqueline C. Barrientos, Paul M. Barr, Anthony R. Mato, Chunxue Shi, Anita Szoke, Chris Abbazio, Gabriel S. Krigsfeld, Jan A. Burger
Journal: Blood
Blood (2022) 140 (Supplement 1): 4159–4161.
https://doi.org/10.1182/blood-2022-163257
Published: 2022
Journal Articles

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

William J Archibald, Anna Barcellos, Jacob Ambrose, Andrew J. Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang, Paul M. Barr
Journal: Blood
Blood (2022) 140 (Supplement 1): 4142–4143.
https://doi.org/10.1182/blood-2022-170596
Published: 2022
Journal Articles

Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment

Jennifer E. Bruno, Christine A. Herne, Andrea M Baran, Karl R. VanDerMeid, Paul M. Barr, Alyssa R. Williams, Sally A. Quataert, Clive S. Zent, Charles C. Chu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4121–4122.
https://doi.org/10.1182/blood-2022-169403
Published: 2022
Journal Articles

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6640–6641.
https://doi.org/10.1182/blood-2022-163509
Published: 2022
Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Clinical Trials & Observations
Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, Elisabeth M. Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry Erba, Richard M. Stone, Mark Litzow, Martin Tallman, Neil E. Kay
Journal: Blood
Blood (2022) 140 (2): 112–120.
https://doi.org/10.1182/blood.2021014960
Published: 2022
Includes: Supplemental data
Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Clinical Trials & Observations
Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer-Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia
Journal: Blood
Blood (2022) 139 (22): 3278–3289.
https://doi.org/10.1182/blood.2021014488
Published: 2022
Includes: Supplemental data
Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Clinical Trials & Observations
Xin Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O’Brien, Jacqueline C. Barrientos, Jose Francisco Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Harry Erba, Richard Stone, Mark R. Litzow, Martin S. Tallman, Tait D. Shanafelt, Neil E. Kay
Journal: Blood
Blood (2021) 138 (26): 2810–2827.
https://doi.org/10.1182/blood.2020010146
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon
Journal: Blood
Blood (2021) 138 (Supplement 1): 528.
https://doi.org/10.1182/blood-2021-148607
Published: 2021
Journal Articles

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Paul M. Barr, Hongli Li, Brian K. Link, Christopher R. Flowers, Richard Burack, Heiko Schöder, Michael L. Leblanc, Oliver Weigert, Alex F. Herrera, David M. Weinstock, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg
Journal: Blood
Blood (2021) 138 (Supplement 1): 2425.
https://doi.org/10.1182/blood-2021-146182
Published: 2021
Journal Articles

Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Danielle S. Wallace, Andrea M. Baran, Jonathan W. Friedberg, Patrick M. Reagan, Carla Casulo, Mijamin Friend, Alyssa R. Williams, Peter D Dakin, Clive S. Zent, Paul M. Barr
Journal: Blood
Blood (2021) 138 (Supplement 1): 2640.
https://doi.org/10.1182/blood-2021-145490
Published: 2021
Journal Articles

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Meghan C. Thompson, Lindsey E. Roeker, Catherine C. Coombs, Jeffrey L. Jensen, Manali Kamdar, Alan Skarbnik, John M. Pagel, Neil Bailey, Jeffrey J. Pu, Ryan Jacobs, Brian T. Hill, Danielle M. Brander, Mazyar Shadman, Chaitra S. Ujjani, Kristen E. Battiato, Celina J. Komari, Guilherme Sacchi De Camargo Correia, Julia H. Aronson, Joanna M Rhodes, Paola Ghione, Bita Fakhri, Paul M. Barr, Craig A. Portell, Nicole Lamanna, Javier Pinilla-Ibarz, Andrew D. Zelenetz, Stephen J Schuster, John N. Allan, Toby A. Eyre, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 2628.
https://doi.org/10.1182/blood-2021-150751
Published: 2021
Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 639.
https://doi.org/10.1182/blood-2021-153146
Published: 2021